Henry C Kitchener professor of gynaecological oncology, Karin Denton consultant cytopathologist, Kate Soldan scientist-epidemiologist, Emma J Crosbie senior lecturer and honorary consultant in gynaecological oncology
Kitchener H C, Denton K, Soldan K, Crosbie E J.
Developing role of HPV in cervical cancer prevention
BMJ 2013; 347 :f4781
doi:10.1136/bmj.f4781
Re: Developing role of HPV in cervical cancer prevention
Very interesting and enlightening article indeed. But I differ from authors at one place where they say -
"......has led to two major developments in cervical cancer control: immunisation as a means of primary prevention and HPV testing in cervical screening, which is poised to replace cytology as the primary screening modality."
Not all cervical cancers are HPV 16 and 18 and 30% are caused by other types, for which HPV quadrivalent vaccine is uneffective. As currently no antiviral agent for cure of HPV is existent, we need to do screening for identification of HPV as said by authors.
However, we need to do cytology for detecting cervical intraepithelial neoplasia (CIN) in order to exise the affected tissue (cone biopsy) as this is the only cure as there is no antiviral agent. More so, for the non 16 and 18 types of HPV for which there is no prevention and cone biopsy is the only cure.
Competing interests: No competing interests